reported side effects
pancreatitis
comprehensive list of adverse effects
adverse effects of didanosine
symptomatology
clinical course of aids
possible adverse effects of other drugs
treatment of hiv infection
expanded access program
eap
adverse effects
drug discontinuation
patients with aids
patients with arc
didanosine
combination with other agents with similar toxicities
incidence of these toxicities
didanosine
patients
didanosine in combination with stavudine
hydroxyurea
increased risk for pancreatitis
hepatotoxicity
severe peripheral neuropathy
side effects
nucleoside reverse transcriptase inhibitor therapy
myopathy
pancreatitis
liver failure
lactic acidosis
direct toxic effect on mitochondria
decreased mitochondrial energy-generating capacity
patients with renal dysfunction
increased risk of toxicity
decreased clearance of didanosine
gastrointestinal side effects
diarrhea
nausea
vomiting
elevated lipase
grades
grades
abdominal pain
pancreatitis
pancreatitis
death
clinical trials of didanosine in combination with other antiretroviral agents
eap in which patients
recommended dosages
incidence at months for pancreatitis
amylase
abdominal pain
anorexia
dyspepsia
flatulence
pancreatitis
including
fatal cases
dry mouth
sialoadenitis
parotid gland enlargement
postmarketing experience
frequency of pancreatitis
dose
phase trials
buffered formulations
incidence
doses
recommended doses
factors
risk of pancreatitis in patients with hiv infection
aids diagnosis
cd
cell count
cells/mm
baseline hyperamylasemia
substantial alcohol intake
elevated liver transaminases
concurrent treatment with pancreatotoxic medications
prior history
resolution
weeks
following discontinuation of therapy
fatal cases
permanent discontinuation of didanosine in patients
developing pancreatitis
rechallenge
recurrent disease
retrospective cohort study
risk of pancreatitis with didanosine combination therapy
patients with hiv
pancreatitis from the virus
direct toxicity of several antiretroviral drugs
lactic acidosis
steatosis
including
fatal cases
use of nucleoside analogs
combination with other antiretroviral agents
caution
administering didanosine
patient with known risk factors for liver disease
cases
patients with no known risk factors
fatal lactic acidosis
pregnant women
combination of didanosine
stavudine with other antiretroviral agents
hyperlactatemia
lactic acidosis
serious concern with the use of didanosine in combination with other antiretrovirals
lactate elevation
common issue in patients on stable antiretroviral therapy
increased levels without acidosis
increased production
release
diminished clearance
hiv
reverse transcriptase inhibitors
competitive inhibitors of dna polymerase
greatest affinity
mitochondria
depletion of mitochondrial dna
cellular respiratory function
increased production of lactic acid
excess lactic acid leaks
cell into systemic circulation
lactic acidosis if hydrogen ions
blood ph.
disturbances in metabolic homeostasis with antiretrovirals
hypertriglyceridemia
insulin resistance
steatohepatitis
liver function
hyperlactatemia
didanosine while lactic acidosis
infrequent occurrence
report
following patients on combined therapy with didanosine
tenofovir
patient
didanosine-related toxicity
lactic acidosis with liver failure after months on didanosine mg/day with tenofovir
safety
efficacy
hiv-infected patients with significant
significant underlying liver disease
combination
antiretroviral therapy
patients
preexisting liver dysfunction
including
chronic active hepatitis
increased rate of liver function abnormalities
including
fatal hepatic side effects
hepatic side effects
lactic acidosis/severe
steatosis
hepatic toxicity
elevated ast
grades
grades
alt
grades
grades
bilirubin
grades
grades
gamma-glutamyltransferase
times uln
grades
fatal hepatic events
patients
combination of hydroxyurea
didanosine
stavudine
addition
fulminant hepatitis
didanosine
death
symptomatic hyperlactatemia/lactic acidosis
hepatic steatosis
noncirrhotic portal hypertension
hepatitis
liver failure
postmarketing experience
hepatotoxicity
hepatic failure
death
postmarketing experience with hydroxyurea
other antiretroviral agents
peripheral neuropathy
patients
eap
trials of didanosine therapy
higher incidence
studies
higher dosages than more recent trials
using lower therapeutic dosages
early trials
patients
advanced hiv disease
one-year rates
developing
developing peripheral neuropathy
latter trials
neuropathy
numbness
pain in the hands
soles of the feet
legs
incidence
patients with a history of neuropathy
low cd
cell counts
cells/mm
following discontinuation of didanosine
neuropathy
weeks
nervous system
side effects
headache
peripheral neurologic symptoms/neuropathy
insomnia
restlessness
seizures
case report of acute gouty arthritis
developing weeks after didanosine
treatment regimen of a patient
receiving ritonavir
hyperuricemia
symptoms
discontinuation of didanosine
short course of indomethacin
metabolic side effects
elevated alkaline phosphatase
times uln
amylase
least times uln
times uln
grades
uric acid
mg/dl
hyperuricemia
patients
eap
case of acute gouty arthritis
diabetes mellitus
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
facial wasting
breast enlargement
cushingoid appearance
hypoglycemia
hyperglycemia
elevated serum
uric acid
serum alkaline phosphatase
serum amylase
serum gamma-glutamyltransferase
postmarketing experience
dermatologic side effects
rash
rash/pruritus
case of cutaneous leukocytoclastic vasculitis
alopecia
postmarketing experience
hematologic side effects
anemia
neutropenia
thrombocytopenia
leukopenia
anemia
thrombocytopenia
postmarketing experience
thrombocytopenia
splenomegaly
early signs of noncirrhotic portal hypertension
postmarketing experience
cardiovascular
side effects
dyspnea
orthopnea
edema
pericarditis
ventricular failure
underlying cardiomyopathy
treatment
buffered formulations
high sodium content
ocular side effects
retinal changes
optic neuritis
diffuse dysfunction of the retinal epithelium with bilateral visual deficit
including night blindness
peripheral visual fold reduction
dry eyes
retinal depigmentation
optic neuritis
postmarketing experience
diffuse dysfunction of the retinal epithelium
patients during therapy with didanosine
patients
bilateral visual deficit
night blindness
peripheral visual fold reduction
symptoms
weeks of therapy
deficits in both patients
discontinuation of didanosine
other side effects
abdominal pain
asthenia
chills/fever
pain
postmarketing experience
musculoskeletal side effects
myalgia
increases in creatine kinase
rhabdomyolysis
including
acute renal failure
hemodialysis
arthralgia
myopathy
postmarketing experience
hypersensitivity side effects
anaphylactoid reaction
postmarketing experience
immunologic side effects
immune reconstitution syndrome
autoimmune disorders
graves
disease
polymyositis
guillain-barre syndrome
setting of immune reconstitution
endocrine side effects
hypertriglyceridemia
impaired glucose tolerance
hyperglycemia
hypoglycemia
insulin-dependent diabetes mellitus
nausea and vomiting
stomach pain
tingling
burning
numbness
pain in the hands
feet
convulsions (seizures)
fever and chills
shortness of breath
skin rash
itching
sore throat
swelling of the feet
lower legs
unusual bleeding
bruising
unusual tiredness
weakness
yellow skin
eyes
stomach discomfort
anxiety
black, tarry stools
bleeding gums
blindness
bloating
blood in the urine
stools
blue-yellow color blindness
blurred vision
change in the color of the eye
chest pain
clay colored stools
cold sweats
coma
confusion
constipation
cool, pale skin
cough
dark urine
decreased appetite
decreased vision
depression
diarrhea
difficulty with moving
difficulty with swallowing
dizziness
dry eyes
dry mouth
eye pain
fast heartbeat
fast, shallow breathing
flushed, dry skin
fruit-like breath odor
general feeling of discomfort
headache
hives
increased hunger
increased thirst
increased urination
indigestion
joint pain
light-colored stools
loss of appetite
loss of consciousness
muscle
cramping
pain
nightmares
difficult urination
pains in the stomach
side
abdomen
radiating
back
red spots on the skin
puffiness
swelling of the eyelids
eyes
face
lips
tongue
stomach pain
fullness
shakiness
sleepiness
slurred speech
sores
ulcers
white spots on the lips
mouth
stomachache
sweating
swollen glands
swollen joints
tightness in the chest
troubled breathing with exertion
unexplained weight loss
unsteadiness or awkwardness
weakness in the arms
hands
legs
feet
difficulty with sleeping
irritability
restlessness
acid
sour stomach
belching
excess air
gas in the stomach
intestines
full feeling
hair loss
thinning of the hair
heartburn
indigestion
lack
loss of strength
passing gas
redistribution
accumulation of body fat